We report the cytogenetic, molecular and biological characterization of a case of B-PLL with a complex karyotype and concurrent abnormalities on the p53 and c-MYC genes. Conventional cytogenetics suggested that both 17q arms were translocated to chromosomes 1q and 14p, respectively, whereas both 17p arms were not identified. In addition, a Burkitt's-like variant translocation t(2;8) was found. Study of loss of heterozygosity at 17p13 and p53 direct sequencing demonstrated the presence of only one copy of the p53 gene. A 27 bp deletion in exon 8 that resulted in the expression of a p53 protein lacking nine amino acids from the DNA binding region was also found. To confirm the presence of one copy of the p53 gene and localize it, fluorescent in situ hybridization (FISH) studies using a p53 gene probe was performed. Only one signal of p53 was visualized. Moreover, the DAPI profile of the chromosome containing the hybridization spot for the p53 probe did correspond to the cytogenetic marker identified as der (14) 
B cell prolymphocytic leukemia (B-PLL) is a distinct and aggressive form of B cell leukemia characterized by a high white cell count and splenomegaly without significant lymphadenopathy. Cytogenetic studies have shown that B-PLL usually presents a complex cytogenetic karyotype 1 with a 14q+ as the most frequent abnormality. Abnormalities on chromosome 17 have also been described. Recently, we reported a high incidence of p53 mutations in B-PLL. 2 In addition, the t(8;14)(q24;q32) translocation -classical of Burkitt's lymphoma -has been reported in 3/23 (13%) of cases. 3 We describe here the cytogenetic, molecular and biological characterization of a case of B-PLL with a complex karyotype and concurrent abnormalities on the p53 and c-MYC genes.
Case presentation
A 73-year-old woman presented in March 1991 with left hypochondrial pain and weakness. On examination, the spleen was enlarged 16 cm below the costal margin, but neither lymphadenopathy nor hepatomegaly were found. Blood counts showed hemoglobin 13 g/dl, platelets 150 × 10 9 /l and WBC (Figure 1 ). The t(2;8)(p12;q24) translocation was cytogenetically identical to the variant Burkitt's translocation that involved the c-MYC gene locus on 8q24 and the Kappa immunoglobulin light chain gene on 2p12. 4 The missing homologues of chromosome 17 appeared to be translocated to chromosomes 1q and 14p and the translocated material was thought to be derived from 17q. The short arms of chromosome 17 were not identified. A detailed molecular analysis of the p53 gene, performed on the patient's DNA at the time of diagnosis, 2 showed one allele loss when loss of heterozygosity at 17p13 was tested using two highly polymorphic probes pYNZ22 and p144-D6 and Southern blot. Furthermore, direct automated sequencing of the highly conserved region of p53 gene (exons 5-9) using termination nucleotides tagged with fluorescent dyes showed germline configuration in all the exons except exon 8, where a 27 bp deletion from codon 275 was found (Figure 2 ). No signal of the remaining allele was found at the site of mutation, confirming LOH. This deletion resulted in the expression of a p53 protein lacking nine amino acids from the DNA binding region when N-and C-terminal antibodies were used.
FISH studies were performed as previously described 5 to confirm the presence of one copy of p53 and to localize it. In a first experiment, digoxigenin-labeled p53 probe specific for genomic sequence of TP53 locus (Oncor, Gaithersburg, MD, USA) was hybridized to the preparations. Only one spot was visualized, confirming that the material (or at least part) of one short arm of chromosome 17 was present in the cells. As shown in Figure 3 , the DAPI profile of the chromosome containing the hybridization spot for the p53 probe could correspond to the cytogenetic marker identified as the der(14) t(14;17), contradicting the cytogenetic results. To define the real nature of the der(14) chromosome, biotin-labeled specific chromosome 14 paint (Cambio, Cambridge, UK), centromerespecific alphoid probe for chromosome 17 labeled with both biotin and digoxigenin and digoxigenin-labeled p53 probes were co-hybridized to the preparations. The 17 centromere and the p53 spots were located in the der(14) (Figure 3 ). This Analysis of p53 exon 8 by PCR direct sequencing using fluorescent termination nucleotides. A chromatogram of control DNA is shown in A. B and C correspond to chromatograms of the PCR product of the patient. A 27 bp deletion was detected in this case. Arrows indicate the beginning and end of the deletion.
demonstrates that the der(14) chromosome contained at least part of the short arm of chromosome 17 with the breakpoint occurring in the long arm. Since this part resembled 17q from the cytogenetic analysis, an inversion or insertion 17p/17q could be considered to have occurred as an alternative rearrangement.
FISH studies were also performed to confirm the involvement of c-MYC on the t(2;8) translocation. Hybridization with a CEPH-Mega YAC clone 904c3 overlapping with c-MYC and a PAC clone 93p9 specific for the Kappa light chain gene probes showed the involvement of c-MYC and Kappa in the t(2;8) translocation (Figure 4) . Thus, FISH allowed the true nature of the rearrangements involving p53 and c-MYC to be determined against the background of a complex and variable karyotype. The der(1)t(1;17)(q42;q11) chromosome resulted in the loss of the short arm of one chromosome 17 (consequently with loss of one allele of the p53 gene), whereas the nature of the marker chromosome could not be addressed by FISH due to lack of material. The significance of the loss of one chromosome 18 as part of the malignant clone remains unclear. The chromosome abnormality identified as t(14;17)(p11;?q11) by conventional cytogenetic was bound to be a complex rearrangement when studied by FISH. The der(14) chromosome contained the centromere of chromosome 17 and distally the p53 gene.
Figure 4
Fluorescence in situ hybridization with c-MYC and Kappa probes. The interphase nuclei showed the two probes in close proximity.
Discussion
We report here a case of B-PLL with concurrent abnormalities on the p53 and c-MYC genes. Activation of the c-MYC oncogene and functional loss of the p53 tumor suppressor gene are among the most frequent recorded genetic lesions in neoplasia. p53 abnormalities are a common event in B-PLL 2, 6 while c-MYC has not been frequently reported in this disease. However, Feneux et al 3 have recently reported 3/23 cases of B-PLL with a t(8;14)(q24;q32) Burkitt's-like translocation. In addition, c-MYC mutations have been reported in one case of B-PLL. 7 The tumor suppressor p53 appears to be the principal gene that protects the cell from cancer caused by DNA damage. Besides arresting cell in G1 to allow DNA to be repaired, wild-type p53 can induce apoptosis. Mutant forms of p53 no longer possess the ability to arrest cell growth and to induce apoptosis. 8 c-MYC is implicated in the control of normal cell growth and its deregulation provides a selective advantage in tumor development. 9 c-MYC can also induce apoptosis in addition to regulating cell proliferation and inhibit cell differentiation. 10 Many previous studies have shown that genetic lesion on both c-MYC and p53 genes co-exist in some lymphoid malignancies such as Burkitt's lymphoma and AIDS-associated Burkitt's lymphoma. 11, 12 These disorders share a common pathogenetic pathway represented by c-MYC activation due to chromosomal translocation in almost 100% of the cases and p53 disruption in 40-60%. Furthermore, using transgenic mice, Blyth and colleagues 13 showed that overexpressed c-MYC and loss of p53 function act synergistically to promote lymphoid tumors, suggesting that those tissues with an abnormally expressed c-MYC protein may gain an additional growth advantage by mutating the p53 gene.
To our knowledge this is the first case of B-PLL reported, having a concomitant inactivation of p53 gene by mutation, and activation of c-MYC gene due to translocation to the Kappa light chain gene. Thus, a Burkitt's-type translocation that may result in c-MYC activation together with a mutated p53 gene may play a critical role in the development of the aggressive form of B-PLL seen in our patient.
